EGFR and non-small cell lung carcinoma: The phase III randomized trial MARQUEE (NCT01244191) studied the dual blockade of EGFR and MET, with small molecule inhibitors Erlotinib and Tivantinib respectively, in stage IIIB/IV non-squamous NSCLC patients with 1 or 2 prior chemotherapies and no prior therapy with an EGFR or MET inhibitor [37].